Int'l : +1-503-894-6022 | Toll Free : +1-800-792-5285 | help@alliedmarketresearch.com
A10492 | Pages: NA | Charts: NA | Tables: NA |
In the pharmaceutical industry, fill and finishis the process of filling vials with vaccine and finishing the process of packaging the medicine for distribution. Many vaccine manufacturers use third parties to fill and finish their vaccines.Fill-finish processing comes after upstream bioprocessing, formation of the active agent by cell culture or fermentation, and downstream purification.This is when the final product has the greatest value, and, thus, the most to lose to a product failure. At these later stages of development, tried-and-true processes tend to be used the most. Innovations can introduce elements of risk, expense, and regulatory work into bioprocess operations. This includes formulation, mixing, or other preparation of active agents into final form, which may include liquid or lyophilized powder, and filling and sealing within final containers, which increasingly include prefilled syringes and other delivery systems.
COVID-19 scenarioanalysis:
Pharmaceutical and biotechnological companies together with governments around the globe are working to combat the COVID-19 outbreak. This is carried out by supporting development of vaccines to schedule for medicines supply chain challenges. Furthermore, there are around 115 vaccine candidates and other 155 molecules that are in the R&D pipeline. Moreover, commonly used drugs such as Hydroxychloroquine have seen huge boost in demand for management of COVID-19. There is an increase in demand for the drug, which has presented huge opportunities for manufacturers of COVID-19 management drugs, as many developed countries are short of the drug. Hence, owing to the demand for vaccine and treatment drugs for COVID-19, the pharmaceutical and biotechnology industry is anticipated to witness a substantial growth in the next few years.
Top impacting factors: Market Scenario Analysis, Trends, Drivers and Impact Analysis
The major factor affecting the industry includes increase technological advancements in the fill-finish manufacturing processes, which are designed such that it meets the market demand. There is a steep growth observed in the biopharmaceutical industry, which would help the industry gain traction in the coming years.Furthermore, surge in adoption of prefilled syringes for parenteral dosage forms would help the industry boost in the next few years.
Surge in number of mergers and acquisitions to propel the market
Increase in number of mergers and acquisitions is anticipated to help the industrygrow in the coming years. For instance, in January 2020, Alcami Corporation, a leading provider of fully-integrated custom end-to-end solutions for pharmaceutical and biologics industries, announced it has acquired TriPharm Services, a new state-of-the-art sterile fill-finish manufacturing center located near Research Triangle Park, North Carolina. The acquisition of TriPharm follows recently announced $17 million expansion of Alcami's sterile fill-finish facility in Charleston, South Carolina.
In conjunction with this acquisition, funds affiliated with Madison Dearborn Partners, LLC, Alcami's existing majority owner, made an additional equity investment to fund Alcami's growth plan and the former majority owner of TriPharm, Ampersand Capital Partners, rolled a portion of its TriPharm ownership interest into an ownership interest in Alcami.
Key benefits of the report:
Questions answered in the fill finish manufacturingmarket research report:
Fill Finish Manufacturing Market - Global Opportunity Analysis and Industry Forecast,
In the pharmaceutical industry, fill and finishis the process of filling vials with vaccine and finishing the process of packaging the medicine for distribution. Many vaccine manufacturers use third parties to fill and finish their vaccines.Fill-finish processing comes after upstream bioprocessing, formation of the active agent by cell culture or fermentation, and downstream purification.This is when the final product has the greatest value, and, thus, the most to lose to a product failure. At these later stages of development, tried-and-true processes tend to be used the most. Innovations can introduce elements of risk, expense, and regulatory work into bioprocess operations. This includes formulation, mixing, or other preparation of active agents into final form, which may include liquid or lyophilized powder, and filling and sealing within final containers, which increasingly include prefilled syringes and other delivery systems.
COVID-19 scenarioanalysis:
Pharmaceutical and biotechnological companies together with governments around the globe are working to combat the COVID-19 outbreak. This is carried out by supporting development of vaccines to schedule for medicines supply chain challenges. Furthermore, there are around 115 vaccine candidates and other 155 molecules that are in the R&D pipeline. Moreover, commonly used drugs such as Hydroxychloroquine have seen huge boost in demand for management of COVID-19. There is an increase in demand for the drug, which has presented huge opportunities for manufacturers of COVID-19 management drugs, as many developed countries are short of the drug. Hence, owing to the demand for vaccine and treatment drugs for COVID-19, the pharmaceutical and biotechnology industry is anticipated to witness a substantial growth in the next few years.
Top impacting factors: Market Scenario Analysis, Trends, Drivers and Impact Analysis
The major factor affecting the industry includes increase technological advancements in the fill-finish manufacturing processes, which are designed such that it meets the market demand. There is a steep growth observed in the biopharmaceutical industry, which would help the industry gain traction in the coming years.Furthermore, surge in adoption of prefilled syringes for parenteral dosage forms would help the industry boost in the next few years.
Surge in number of mergers and acquisitions to propel the market
Increase in number of mergers and acquisitions is anticipated to help the industrygrow in the coming years. For instance, in January 2020, Alcami Corporation, a leading provider of fully-integrated custom end-to-end solutions for pharmaceutical and biologics industries, announced it has acquired TriPharm Services, a new state-of-the-art sterile fill-finish manufacturing center located near Research Triangle Park, North Carolina. The acquisition of TriPharm follows recently announced $17 million expansion of Alcami's sterile fill-finish facility in Charleston, South Carolina.
In conjunction with this acquisition, funds affiliated with Madison Dearborn Partners, LLC, Alcami's existing majority owner, made an additional equity investment to fund Alcami's growth plan and the forme
Key benefits of the report:
Questions answered in the fill finish manufacturingmarket research report:
Key Market Segments
Key Market Players
